AR035551A1 - Polimorfos de la sal difosfato de un derivado de 4''-sustituido-9-desoxo-9a-aza-9a-homoeritromicina, su composicion farmaceutica, procedimiento de preparacion y uso en medicina - Google Patents

Polimorfos de la sal difosfato de un derivado de 4''-sustituido-9-desoxo-9a-aza-9a-homoeritromicina, su composicion farmaceutica, procedimiento de preparacion y uso en medicina

Info

Publication number
AR035551A1
AR035551A1 ARP000103255A ARP000103255A AR035551A1 AR 035551 A1 AR035551 A1 AR 035551A1 AR P000103255 A ARP000103255 A AR P000103255A AR P000103255 A ARP000103255 A AR P000103255A AR 035551 A1 AR035551 A1 AR 035551A1
Authority
AR
Argentina
Prior art keywords
mammals
crystalline
diphosphate
diphosphate salt
methyl
Prior art date
Application number
ARP000103255A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR035551A1 publication Critical patent/AR035551A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Dos polimorfos de una sal difosfato cristalina de (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[ [2,6-dideoxi-3-C-metil-3-O-metil-4-C- [propilamino)amino]metil]-alfa-L-ribo-hexopiranosil]-oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-11-[[3,4,6-trideoxi-3-(dimetilamino)-beta-D-xilo-hexopiranosil]-oxi]-1-oxa-6-azaciclopentadecan-15-ona que es útil como agente antibacteriano y antiprotozoario en mamíferos. También se describen a composiciones farmacéuticas que contienen la base libre de la sal difosfato y su uso para la preparación de medicamentos para el tratamiento de infecciones bacterianas y protozoarias en mamíferos, mediante la administración de la base libre de la sal difosfato a mamíferos que requieren dicho tratamiento. La base libre de la sal difosfato de la presente posee una potente actividad contra diversas infecciones bacterianas y protozoarias cuando se administra por vía parenteral a mamíferos. Se describe también un procedimiento de preparación del compuesto, según fórmula (1) donde n es un número de 0 a 8 y los polimorfos se seleccionan entre el grupo compuesto por: a) una mesofase cristalina esméctica de un cristal líquido; y b) un disfosfato cristalino que presente el modelo de difracción de rayos X de polvo. N° pico 1 2 3 4 5 6 7 8 9 10 Espacio d 16,2 12,4 10,8 9,0 6,9 6,5 6,2 5,4 5,1 4,9
ARP000103255A 1999-06-30 2000-06-28 Polimorfos de la sal difosfato de un derivado de 4''-sustituido-9-desoxo-9a-aza-9a-homoeritromicina, su composicion farmaceutica, procedimiento de preparacion y uso en medicina AR035551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14168199P 1999-06-30 1999-06-30

Publications (1)

Publication Number Publication Date
AR035551A1 true AR035551A1 (es) 2004-06-16

Family

ID=22496734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103255A AR035551A1 (es) 1999-06-30 2000-06-28 Polimorfos de la sal difosfato de un derivado de 4''-sustituido-9-desoxo-9a-aza-9a-homoeritromicina, su composicion farmaceutica, procedimiento de preparacion y uso en medicina

Country Status (42)

Country Link
US (3) US6465437B1 (es)
EP (1) EP1189913B1 (es)
JP (1) JP2003503506A (es)
KR (1) KR100442508B1 (es)
CN (2) CN101220067A (es)
AP (1) AP2001002370A0 (es)
AR (1) AR035551A1 (es)
AT (1) ATE286906T1 (es)
AU (1) AU772277B2 (es)
BG (1) BG65587B1 (es)
BR (1) BR0012091A (es)
CA (1) CA2376748C (es)
CO (1) CO5190679A1 (es)
CZ (1) CZ20014571A3 (es)
DE (1) DE60017399T2 (es)
EA (1) EA004235B1 (es)
EC (1) ECSP003555A (es)
EE (1) EE05068B1 (es)
ES (1) ES2233380T3 (es)
GT (2) GT200000105A (es)
HN (1) HN2000000090A (es)
HR (1) HRP20010919B1 (es)
HU (1) HUP0201693A3 (es)
IL (1) IL146408A0 (es)
IS (1) IS6159A (es)
MA (1) MA26745A1 (es)
MX (1) MXPA02000058A (es)
MY (1) MY133360A (es)
NO (1) NO20016221L (es)
OA (1) OA11965A (es)
PA (1) PA8496901A1 (es)
PE (1) PE20010287A1 (es)
PL (1) PL201891B1 (es)
PT (1) PT1189913E (es)
SK (1) SK286243B6 (es)
TN (1) TNSN00143A1 (es)
TR (1) TR200103834T2 (es)
UA (1) UA71013C2 (es)
UY (1) UY26221A1 (es)
WO (1) WO2001002414A1 (es)
YU (1) YU88701A (es)
ZA (1) ZA200110453B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition
US6791660B1 (en) * 2002-02-12 2004-09-14 Seiko Epson Corporation Method for manufacturing electrooptical device and apparatus for manufacturing the same, electrooptical device and electronic appliances
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2013013834A1 (en) 2011-07-27 2013-01-31 Farma Grs, D.O.O. New crystalline forms of tulathromycin
CN106008622A (zh) * 2016-08-02 2016-10-12 海门慧聚药业有限公司 泰拉霉素新晶型及其制备
CN110885351A (zh) * 2019-12-17 2020-03-17 海门慧聚药业有限公司 泰拉霉素磷酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
HN1998000086A (es) * 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
JP2003512290A (ja) * 1997-09-10 2003-04-02 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての8a−アザライド
UA70972C2 (uk) * 1998-11-20 2004-11-15 Пфайзер Продактс Інк. 13-членні азаліди і їх застосування як антибіотиків
OA11876A (en) * 1999-05-18 2006-03-27 Pfizer Prod Inc Novel crystalline forms of a macrolide antibiotic.
US6465437B1 (en) * 1999-06-30 2002-10-15 Pfizer Inc. Diphosphate salt of a 4″-substituted-9-deoxo-9A-AZA-9A- homoerythromycin derivative and its pharmaceutical composition

Also Published As

Publication number Publication date
DE60017399D1 (de) 2005-02-17
KR20020016875A (ko) 2002-03-06
EP1189913A1 (en) 2002-03-27
US20040209826A1 (en) 2004-10-21
NO20016221D0 (no) 2001-12-19
HRP20010919B1 (en) 2005-06-30
PE20010287A1 (es) 2001-03-05
CN101220067A (zh) 2008-07-16
UA71013C2 (uk) 2004-11-15
EA200101178A1 (ru) 2002-06-27
NO20016221L (no) 2001-12-19
ATE286906T1 (de) 2005-01-15
PA8496901A1 (es) 2002-08-26
HUP0201693A2 (en) 2002-10-28
CA2376748A1 (en) 2001-01-11
GT200000105AA (es) 2001-12-20
EP1189913B1 (en) 2005-01-12
US6465437B1 (en) 2002-10-15
CO5190679A1 (es) 2002-08-29
YU88701A (sh) 2004-09-03
MXPA02000058A (es) 2002-07-02
PT1189913E (pt) 2005-04-29
OA11965A (en) 2006-04-12
IS6159A (is) 2001-11-13
TR200103834T2 (tr) 2002-05-21
AP2001002370A0 (en) 2001-12-31
ECSP003555A (es) 2002-01-25
ES2233380T3 (es) 2005-06-16
JP2003503506A (ja) 2003-01-28
PL201891B1 (pl) 2009-05-29
EA004235B1 (ru) 2004-02-26
ZA200110453B (en) 2003-03-04
US7297682B2 (en) 2007-11-20
KR100442508B1 (ko) 2004-07-30
GT200000105A (es) 2001-12-20
EE200100699A (et) 2003-02-17
SK18922001A3 (sk) 2002-04-04
IL146408A0 (en) 2002-07-25
AU772277B2 (en) 2004-04-22
CN1358188A (zh) 2002-07-10
BR0012091A (pt) 2002-04-02
HN2000000090A (es) 2001-04-20
WO2001002414A1 (en) 2001-01-11
US20030092642A1 (en) 2003-05-15
MY133360A (en) 2007-11-30
MA26745A1 (fr) 2004-12-20
TNSN00143A1 (fr) 2005-11-10
CZ20014571A3 (cs) 2002-04-17
PL352900A1 (en) 2003-09-22
BG106123A (en) 2002-05-31
DE60017399T2 (de) 2006-03-30
AU4943900A (en) 2001-01-22
CA2376748C (en) 2006-03-14
EE05068B1 (et) 2008-08-15
HUP0201693A3 (en) 2003-03-28
SK286243B6 (sk) 2008-06-06
BG65587B1 (bg) 2009-01-30
HRP20010919A2 (en) 2003-02-28
US6861412B2 (en) 2005-03-01
UY26221A1 (es) 2001-01-31

Similar Documents

Publication Publication Date Title
AU2014248014B2 (en) Macrolides and methods of their preparation and use
EP0778022B1 (en) Use of rifamycin derivatives for the treatment of chlamydia infectous diseases
NZ504986A (en) Erythromycin and azalide derivatives and pharmaceutical compositions thereof, useful as antibacterial agents and antoprotozoa agents
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
CN114555077A (zh) 作为抗病毒剂的Patentiflorin A类似物
JPS61251696A (ja) 新規化合物,その製法及びそれを含む医薬組成物
AR035551A1 (es) Polimorfos de la sal difosfato de un derivado de 4''-sustituido-9-desoxo-9a-aza-9a-homoeritromicina, su composicion farmaceutica, procedimiento de preparacion y uso en medicina
FI830654A0 (fi) 4 -epi-erytromycin a och derivat daerav som nyttiga antibakteriella medel
RU94042916A (ru) 9a-n - (n'-карбамоил) - и 9a-n - (n'-тиокарбамоил) производные 9-деоксо- 9a - аза - 9a - гомоэтирмицина а, способ их получения и фармкомпозиция на их основе
RU94046456A (ru) Новые аналоги витамина д, способ получения, фармацевтическая композиция, способ лечения
CN100348605C (zh) 秋水仙碱苷类似物
JPS5610200A (en) Anthracycline glycoside* its manufacture and medicinal composition containing same for tumor treatment
DE3060481D1 (en) Anthracycline glycosides, methods for the production thereof and therapeutical compositions containing same
HU194809B (en) Process for producing acyl-enamide compounds and pharmaceutical compositions containing them as active components
AP9801235A0 (en) Erythromycin derivatives.
ZA794155B (en) New aminoglycosides derived from desoxystreptamine,and their salts,their preparation process,their application as medicaments and the pharmaceutical compounds containing them
US4169890A (en) Pharmaceutical composition containing 5"-amino-3',5"-dideoxy-ribostamycin and intermediate compounds
CN104961785A (zh) 一种新型酰内酯衍生物及其制备方法
IL40151A (en) Aminoglycoside antibiotics and a method for their preparation from the micromonosphere
JP2006328080A (ja) クラミジア感染症治療剤
RU2012118247A (ru) Полиморфные и псевдополиморфные формы фармацевтического соединения

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure